New treatments emerge for Alzheimer's agitation, moving beyond off-label drug use with modest benefits.
Denali Therapeutics halted the SAR443820 trial after a phase 2 study failed to slow functional...
Expert discusses TDP-43 role in ALS research, a protein present in 97% of ALS patients,...
Eight new muscular dystrophy therapies show promise in targeting disease mechanisms, moving beyond traditional care...
Football players face a fourfold higher risk of developing ALS, according to a 2021 study,...
The FDA fast-tracks satralizumab for MOGAD, a rare autoimmune disease. This decision could make it...
Gene therapy shows promise for seizure patients with sustained reductions in seizure frequency and improved...
A 20% sugar tax could add half‑million life years and cut dental disease, showing levy...
Avian flu funding in Australia draws criticism as $20 million aid falls short of the...
Data centre climate concerns rise as Australia backs away from renewable mandates, prompting Nepal’s tech...